CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

hydrocortisoneWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug96 AVM0703 Wiki 1.00
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (7)

Name (Synonyms) Correlation
D011665 Pulmonary Valve Insufficiency NIH 0.41
D013577 Syndrome NIH 0.11
D055371 Acute Lung Injury NIH 0.10
D012127 Respiratory Distress Syndrome, Newborn NIH 0.10
D012128 Respiratory Distress Syndrome, Adult NIH 0.09
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0010444 Pulmonary insufficiency HPO 0.41

There is one clinical trial.

Clinical Trials

1 A Randomized, Double-Blind, Placebo-Controlled, Phase 1/2 Study Evaluating AVM0703 in Patients With COVID-19

This is a randomized, double-blind, placebo-controlled, single-ascending dose study of AVM0703 administered as a single intravenous (IV) infusion to patients with COVID-19. The study is designed to evaluate the safety, tolerability, and pharmacokinetics of single-ascending dosing of AVM0703 in patients with COVID-19.

NCT04366115 COVID-19 Drug: AVM0703 Drug: Placebo Drug: hydrocortisone

Primary Outcomes

Description: The primary endpoint of the Phase 1 portion of the study is to evaluate the safety of AVM0703 in subjects with severe or life-threatening COVID-19 infection, and to identify the RP2D.

Measure: Dose-Limiting Toxicities

Time: 0-12 months

Description: The primary endpoint of the Phase 1/2 portion of the study is to evaluate the efficacy of AVM0703 in subjects with severe or life-threatening COVID-19 infection.

Measure: 28 day all-cause mortality will be a primary end point for Phase 1 and 2

Time: 0-12 months

No related HPO nodes (Using clinical trials)